IMP321 Phase 1 Study in Advanced or Metastatic Renal Cell Carcinoma Patients (P003)

Trial Profile

IMP321 Phase 1 Study in Advanced or Metastatic Renal Cell Carcinoma Patients (P003)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs IMP 321 (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Immutep
  • Most Recent Events

    • 12 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
    • 26 Apr 2008 The expected completion date for this trial has been extended from 1 Apr 2008 to 1 Nov 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top